Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Association between tTMB and clinical outcomes with pembrolizumab alone in PD...

Prof Roy Herbst - Yale Cancer Center, New Haven, USA

Association between tTMB and clinical outcomes with pembrolizumab alone in PD-L1-positive advanced NSCLC in KEYNOTE-010 and -042 ( Prof Roy Herbst - Yale Cancer Center, New Haven, USA )

IMPALA results: Lefitolimod vs standard of care in metastatic colorectal cancer

Dr Ramon Salazar - Catalan Institute of Oncology, Barcelona, Spain

IMPALA results: Lefitolimod vs standard of care in metastatic colorectal cancer ( Dr Ramon Salazar - Catalan Institute of Oncology, Barcelona, Spain )

AMG 510: A novel molecule targeting KRAS G12C mutant solid tumours

Prof Marwan Fakih - City of Hope National Medical Center, Duarte, USA

AMG 510: A novel molecule targeting KRAS G12C mutant solid tumours ( Prof Marwan Fakih - City of Hope National Medical Center, Duarte, USA )

MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast...

Prof Susan Domchek - University of Pennsylvania, Pennsylvania, USA

MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast cancer ( Prof Susan Domchek - University of Pennsylvania, Pennsylvania, USA )

Blood first assay screening in patients with ALK positive NSCLC

Prof Shirish Gadgeel - University of Michigan, Ann Arbor, USA

Blood first assay screening in patients with ALK positive NSCLC ( Prof Shirish Gadgeel - University of Michigan, Ann Arbor, USA )

Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative...

Dr Véronique Diéras - Centre Eugène Marquis, Rennes, France

Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer ( Dr Véronique Diéras - Centre Eugène Marquis, Rennes, France )

CUPISCO: Identifying carcinoma of unknown primary patients according to ESMO...

Prof Jeffrey S. Ross - Albany Medical Center, Albany, USA

CUPISCO: Identifying carcinoma of unknown primary patients according to ESMO guidelines ( Prof Jeffrey S. Ross - Albany Medical Center, Albany, USA )

CheckMate 459: Safety and efficacy of nivolumab versus sorafenib as a first...

Dr Thomas Yau - The University of Hong Kong, Hong Kong

CheckMate 459: Safety and efficacy of nivolumab versus sorafenib as a first-line treatment in advanced hepatocellular carcinoma ( Dr Thomas Yau - The University of Hong Kong, Hong Kong )

Optimal timing of radiotherapy following radical prostatectomy

Prof Chris Parker - The Royal Marsden Hospital, London, UK

Optimal timing of radiotherapy following radical prostatectomy ( Prof Chris Parker - The Royal Marsden Hospital, London, UK )

Safety and tolerability of AVB500 in platinum-resistant recurrent ovarian cancer

Dr Gail McIntyre - CSO, Aravive Biologics, Houston, Texas

Safety and tolerability of AVB500 in platinum-resistant recurrent ovarian cancer ( Dr Gail McIntyre - CSO, Aravive Biologics, Houston, Texas )

INVICTUS: Assessing the safety and efficacy of ripretinib in patients with...

Prof Margaret von Mehren - Fox Chase Cancer Center, Philadelphia, USA

INVICTUS: Assessing the safety and efficacy of ripretinib in patients with advanced gastrointestinal stromal tumours ( Prof Margaret von Mehren - Fox Chase Cancer Center, Philadelphia, USA )

Using PARP inhibitors to improve quality of life for patients with metastatic...

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

Using PARP inhibitors to improve quality of life for patients with metastatic breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

More from ecancer